MAP1LC3C and urinary bladder carcinoma: Further analysis revealed a consistent overall reduction in MAP1LC3C expression across a minimum of seven cancer types, including esophageal carcinoma, stomach adenocarcinoma, bladder carcinoma, colon adenocarcinoma, rectum adenocarcinoma, lung adenocarcinoma and head and neck squamous cell carcinoma (Fig. S1A-G), suggesting a selection advantage for tumor cells with decreased MAP1LC3C expression.